Gert Ossenkoppele

Affiliated with

Research Area

Biography

Gert Ossenkoppele has not added Biography.
If you are Gert Ossenkoppele and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 36	2018

Other Publications

Article	Year
Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells. PloS one\| PubMed ID: 24244383	2013
ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review. The Journal of pathology\| PubMed ID: 12692835	2003
Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia. Haematologica\| PubMed ID: 12745269	2003
Procedures for the expansion of CD14(+) precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy. Immunotherapy\| PubMed ID: 24188673	2013
Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood\| PubMed ID: 12036886	2002
Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. Haematologica\| PubMed ID: 12604403	2003
Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation. Cancer immunology, immunotherapy : CII\| PubMed ID: 12690520	2003
Novel multiparameter flow cytometry assay using Syto16 for the simultaneous detection of early apoptosis and apoptosis-corrected P-glycoprotein function in clinical samples. Cytometry. Part B, Clinical cytometry\| PubMed ID: 12949955	2003
Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells. Haematologica\| PubMed ID: 12969806	2003
Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications. Anti-cancer drugs\| PubMed ID: 15014351	2004
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood\| PubMed ID: 15070662	2004
Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer research\| PubMed ID: 15313888	2004
Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma. Current opinion in hematology\| PubMed ID: 15548997	2004
Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden. Experimental hematology\| PubMed ID: 15661405	2005
Minimal residual disease in acute myeloid leukemia is predicted by an apoptosis-resistant protein profile at diagnosis. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 15814631	2005
Quantification of T-cell-mediated apoptosis in heterogeneous leukemia populations using four-color multiparameter flow cytometry. Cytometry. Part A : the journal of the International Society for Analytical Cytology\| PubMed ID: 15895438	2005
Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 16000576	2005
Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization. Immunobiology\| PubMed ID: 16164032	2005
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 16166428	2005
Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia. Haematologica\| PubMed ID: 16531258	2006
Principles of dendritic cell-based immunotherapy in myeloid leukemia. Immunobiology\| PubMed ID: 16920505	2006
Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia. Immunobiology\| PubMed ID: 16920506	2006
Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood\| PubMed ID: 17068146	2007
Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 17170077	2007
CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Annals of hematology\| PubMed ID: 17340137	2007
Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 17401010	2007
Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells. Blood\| PubMed ID: 17916749	2008
Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival. Leukemia & lymphoma\| PubMed ID: 17926185	2008
Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood\| PubMed ID: 17971483	2008
Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 18056177	2007
Positive selection for CD90 as a purging option in acute myeloid leukemia stem cell transplants. Cytometry. Part B, Clinical cytometry\| PubMed ID: 18061946	2008
Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia. Leukemia & lymphoma\| PubMed ID: 18569637	2008
Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia. Haematologica\| PubMed ID: 19042917	2009
Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem cells (Dayton, Ohio)\| PubMed ID: 19096043	2008
Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome. Haematologica\| PubMed ID: 19229054	2009
Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. European journal of cancer (Oxford, England : 1990)\| PubMed ID: 19321337	2009
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica\| PubMed ID: 19546437	2009
A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment. American journal of hematology\| PubMed ID: 19658186	2009
Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses. Haematologica\| PubMed ID: 19903675	2010
Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood\| PubMed ID: 20038788	2010
Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles. The Journal of pathology\| PubMed ID: 20087881	2010
Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells. Haematologica\| PubMed ID: 20421276	2010
New approaches for the detection of minimal residual disease in acute myeloid leukemia. Current hematologic malignancy reports\| PubMed ID: 20425359	2007
Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia. Immunotherapy\| PubMed ID: 20635890	2010
Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia. Immunotherapy\| PubMed ID: 20635891	2010
Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes. Cancer immunology, immunotherapy : CII\| PubMed ID: 20820776	2010
Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation. Cancer immunology, immunotherapy : CII\| PubMed ID: 20859626	2011
Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells. Cancer research\| PubMed ID: 21310823	2011
Challenging diagnosis in a patient with clear lymphoid immunohistochemical features and myeloid morphology: mixed phenotype acute leukemia with erythrophagocytosis. Leukemia research\| PubMed ID: 21334744	2011
Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. British journal of haematology\| PubMed ID: 21385170	2011
Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells. Immunotherapy\| PubMed ID: 21463196	2011
Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD. Haematologica\| PubMed ID: 21606167	2011
Class II-associated invariant chain peptide expression represents a novel parameter for flow cytometric detection of acute promyelocytic leukemia. The American journal of pathology\| PubMed ID: 21907692	2011
Azacitidine differentially affects CD4(pos) T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes. Leukemia research\| PubMed ID: 22503132	2012
Towards a joint definition of European hematology. Haematologica\| PubMed ID: 22556351	2012
Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells. PloS one\| PubMed ID: 22563374	2012
Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation. Oncoimmunology\| PubMed ID: 22720245	2012
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leukemia & lymphoma\| PubMed ID: 22916713	2013
Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Sw... Blood\| PubMed ID: 23047822	2012
A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin. Cytometry. Part B, Clinical cytometry\| PubMed ID: 23325578	2013
Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood\| PubMed ID: 23325837	2013
MicroRNA profiling can classify acute leukemias of ambiguous lineage as either acute myeloid leukemia or acute lymphoid leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 23444217	2013
Autologous Stem Cell Transplantation in elderly Acute Myeloid Leukemia. Mediterranean journal of hematology and infectious diseases\| PubMed ID: 23505606	2013
MRD in AML: time for redefinition of CR? Blood\| PubMed ID: 23520326	2013
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch... Annals of hematology\| PubMed ID: 23572137	2013
Priming of PRAME- and WT1-specific CD8T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy. Oncoimmunology\| PubMed ID: 23734332	2013
Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology ... European journal of cancer (Oxford, England : 1990)\| PubMed ID: 23876833	2013
Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines. Immunotherapy\| PubMed ID: 23902555	2013
Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines. Cancer immunology, immunotherapy : CII\| PubMed ID: 24384837	2014
Positioning of aminopeptidase inhibitors in next generation cancer therapy. Amino acids\| PubMed ID: 24385243	2014
Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. Cytometry. Part B, Clinical cytometry\| PubMed ID: 24431028	2014
Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. Cytometry. Part B, Clinical cytometry\| PubMed ID: 24474614	2014
Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication. Cancer research\| PubMed ID: 24477595	2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nil... Haematologica\| PubMed ID: 24532039	2014
High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia. Leukemia research\| PubMed ID: 24731748	2014
Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia\| PubMed ID: 25113226	2015
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer cell\| PubMed ID: 25132497	2014
Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PloS one\| PubMed ID: 25244440	2014
Genomic amplification of MYC as double minutes in a patient with APL-like leukemia. Molecular cytogenetics\| PubMed ID: 25392715	2014
MRD in AML: it is time to change the definition of remission. Best practice & research. Clinical haematology\| PubMed ID: 25455276	2014
How I treat the older patient with acute myeloid leukemia. Blood\| PubMed ID: 25515963	2015
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukem... Haematologica\| PubMed ID: 25527562	2015
loading of skin dendritic cells with apoptotic bleb-derived antigens for the induction of tumor-directed immunity. Oncoimmunology\| PubMed ID: 25610730	2014
Immunophenotyping for diagnosis and prognosis in MDS: ready for general application? Best practice & research. Clinical haematology\| PubMed ID: 25659726	2015
Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes. Haematologica\| PubMed ID: 25749828	2015
Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. Haematologica\| PubMed ID: 26160876	2015
Differential capacity of human interleukin-4 and interferon-α monocyte-derived dendritic cells for cross-presentation of free versus cell-associated antigen. Cancer immunology, immunotherapy : CII\| PubMed ID: 26216454	2015
A Human Cell Line Model for Interferon-α Driven Dendritic Cell Differentiation. PloS one\| PubMed ID: 26252775	2015
Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival ... Oncotarget\| PubMed ID: 26496029	2016
Application of flow cytometry for myelodysplastic syndromes: Pitfalls and technical considerations. Cytometry. Part B, Clinical cytometry\| PubMed ID: 26517178	2016
Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012. European journal of haematology\| PubMed ID: 26519944	2016
Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid. Blood\| PubMed ID: 26582376	2016
Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. The Lancet. Haematology\| PubMed ID: 26686044	2015
Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias. European journal of cancer (Oxford, England : 1990)\| PubMed ID: 26720403	2016
Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia. Haematologica\| PubMed ID: 26721801	2016
Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System. European journal of cancer (Oxford, England : 1990)\| PubMed ID: 26798967	2016
How to assess minimal residual disease in pediatric and adult acute myeloid leukemia? Translational pediatrics\| PubMed ID: 26835296	2013
Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 27006491	2016
Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes. Haematologica\| PubMed ID: 27658438	2017
MRD in AML: does it already guide therapy decision-making? Hematology. American Society of Hematology. Education Program\| PubMed ID: 27913502	2016
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood\| PubMed ID: 28049642	2017
Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial. Genes, chromosomes & cancer\| PubMed ID: 28236351	2017
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. Journal of cancer research and clinical oncology\| PubMed ID: 28364360	2017
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica\| PubMed ID: 28522574	2017
The interference of genetic associations in establishing the prognostic value of the immunophenotype in acute myeloid leukemia. Cytometry. Part B, Clinical cytometry\| PubMed ID: 28646564	2018
Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference? Cancers\| PubMed ID: 28665351	2017
Validation of and proposals for refinements of the WHO 2016 classification for myelodysplastic syndromes. American journal of hematology\| PubMed ID: 28741674	2017
Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party. Blood\| PubMed ID: 29330221	2018